Drug
Ipg11406
Ipg11406: highest development phase Phase 2, developed by Nanjing Immunophage Biotech Co., Ltd. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Nanjing Immunophage Biotech Co., Ltd
Trials
| Drug | Phase | Indication |
|---|---|---|
| IPG11406 NCT07535489 | Phase 2 | Moderately to Severely Active Ulcerative Colitis (UC) |
Latest
No recent events.
Follow Ipg11406 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.